<DOC>
	<DOCNO>NCT02354846</DOCNO>
	<brief_summary>An Observational Study Evaluating Efficacy Safety Preemptive Antiviral Therapy Tenofovir HBsAg-positive Patients Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy ( SPEED study )</brief_summary>
	<brief_title>An Observational Study Evaluating Efficacy Safety Preemptive Antiviral Therapy With Tenofovir HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy ( SPEED Study )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Males female age than18 HBsAgpositive DLBCL patient ( possible enrol patient combine DLBCL low grade lymphoma follicular lymphoma ) Previously untreated DLBCL patient suitable receive RCHOP chemotherapy Serum ALT 2 x ULN ( include normal ALT ) Life expectancy 6 month A negative serum urine pregnancy test prior treatment must available pre menopausal woman woman 1 year onset menopause . Informed consent Other subtype lymphoma except DLBCL DLBCL patient NOT suitable receive RCHOP chemotherapy OR plan receive chemotherapy patient treat antiviral therapy know activity HBV ( e.g. , alphainterferon , lamivudine , telbivudine , clevudine , adefovir , entecavir tenofovir ) within previous 6 month . evidence hepatocellular carcinoma . evidence decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>